The anti-cancer drugs and drugs with clinically major side effects were omitted. The remaining 35 drugs were selected for further comparative analysis. This included anti-HIV, anti-HCV, anti-Inflammatory, Lung disease, anti-migraine activity, and anti-parasitic activity. Along with nine clinically reported promising anti-COVD19 drugs also included for further analysis. The binding energy of selected 35 compounds graded in five grades displaying dark green, light green, yellow, orange and red for easy comparison. Concerning anti-COVID19 activity against single and multiple target analysis, the best results obtained for 8 drugs from anti-HCV followed by 7 anti-HIV and 3 currently clinically used drugs. In addition to that, 1 drug from an anti-inflammatory and anti-migraine group also had a good docking score. The overall analysis presented the comparatively better scoring of the selected drug in this study over currently clinically applied drugs for COVID19 treatment (Figure ) To narrow down the number of drug combinations and removing drug acting on the same target binding energy replaced with docking rank. Based on dock rank 10 drugs selected for further analysis (Figure ). To reduce the drug for treatment and avoid duplication, the drug acting on the same target was removed. Consequently, the combination of Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine Ergotamine drug figured out as a potential cocktail for COVID19 treatment (Figure ).